Research ArticleTheranostics
NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
Thomas A. Hope, Amanda Abbott, Karen Colucci, David L. Bushnell, Linda Gardner, William S. Graham, Sheila Lindsay, David C. Metz, Daniel A. Pryma, Michael G. Stabin and Jonathan R. Strosberg
Journal of Nuclear Medicine July 2019, 60 (7) 937-943; DOI: https://doi.org/10.2967/jnumed.118.230607
Thomas A. Hope
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
2Department of Radiology, San Francisco VA Medical Center, San Francisco, California
Amanda Abbott
3Dana-Farber Cancer Institute, Boston, Massachusetts
Karen Colucci
4Lehigh Valley Health Network, Allentown, Pennsylvania
David L. Bushnell
5Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa
6Iowa City VA Medical Center, Iowa City, Iowa
Linda Gardner
7Department of Nuclear Medicine, University of California, Los Angeles, Los Angeles, California
William S. Graham
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Sheila Lindsay
8Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California
David C. Metz
9Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
Daniel A. Pryma
10Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
Michael G. Stabin
11NV5/Dade Moeller, Richland, Washington; and
Jonathan R. Strosberg
12Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 7
July 1, 2019
NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
Thomas A. Hope, Amanda Abbott, Karen Colucci, David L. Bushnell, Linda Gardner, William S. Graham, Sheila Lindsay, David C. Metz, Daniel A. Pryma, Michael G. Stabin, Jonathan R. Strosberg
Journal of Nuclear Medicine Jul 2019, 60 (7) 937-943; DOI: 10.2967/jnumed.118.230607
NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
Thomas A. Hope, Amanda Abbott, Karen Colucci, David L. Bushnell, Linda Gardner, William S. Graham, Sheila Lindsay, David C. Metz, Daniel A. Pryma, Michael G. Stabin, Jonathan R. Strosberg
Journal of Nuclear Medicine Jul 2019, 60 (7) 937-943; DOI: 10.2967/jnumed.118.230607
Jump to section
- Article
- Abstract
- PREAMBLE
- BACKGROUND
- TREATMENT OVERVIEW
- PATIENT SCREENING
- SOMATOSTATIN ANALOG THERAPY
- TREATMENT LOCATION
- ROOM PREPARATION
- PATIENT PREPARATION
- AMINO ACID SOLUTIONS
- ANTIEMETIC MEDICATIONS
- RADIOPHARMACEUTICAL ADMINISTRATION
- DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS
- PATIENT MONITORING AND POTENTIAL REACTIONS
- RADIATION SAFETY
- DOSIMETRY AND POSTTREATMENT IMAGING
- TOXICITY
- FOLLOW-UP
- CONCLUSION
- REFERENCES
- Figures & Data
- Supplemental
- Info & Metrics
Related Articles
Cited By...
- 177Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods
- Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients
- The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy
- Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans
- Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK
- Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
- Single-Time-Point Imaging for Dosimetry After [177Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection
- Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
- 177Lu-PSMA Therapy
- 90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study
- Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
- A Case of 177Lu-DOTATATE Therapy Without the Use of Antiemetics
- Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
- A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy
- Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy
- Patient Travel Concerns After Treatment with 177Lu-DOTATATE
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine